Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to determine the onset time, duration of action and effect on intubation conditions of mivacurium 0.2 mg/kg in elderly patients with age ≥ 80 years and in young patients aged 18 - 40 years.
The aim of this study is to determine the onset time, duration of action and effect on intubation conditions of mivacurium 0.2 mg/kg in elderly patients with age ≥ 80 years and in young patients aged 18 - 40 years. The hypothesis of this study is that mivacurium administered in elderly patients (>80 years) has a longer onset time and duration of action compared to younger patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Elderly | patients aged 80 years or older |
| |
| Young | patients aged 18-40 years |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mivacurium | Drug | 0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower |
|
| Measure | Description | Time Frame |
|---|---|---|
| Onset time | the time from the start of the injection of mivacurium to train-of-four (TOF) count of 0 monitored by acceleromyography | within 10 minutes after administration of mivacurium |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of action | Duration of action is defined as time from start of mivacurium injection to reappearance of TOF ratio > 0.9. | within 90 minutes after administration of mivacurium |
| Intubation conditions IDS |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Elderly patients (≥ 80 years) and younger patients (18-40 years) scheduled for elective surgery
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matias Vested | Rigshospitalet University of Copenhagen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet | Copenhagen | 2100 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077590 | Mivacurium |
| ID | Term |
|---|---|
| D007546 | Isoquinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Butyrylcholinesterase activity determined by a blood sample
|
intubation conditions are rated according to intubating difficulty score IDS when TOF-ratio is 0.
| within 10 minutes after administration of mivacurium |
| Intubation conditions Fuchs-Buder | intubation conditions are rated according to Fuchs-Buder score when TOF-ratio is 0. | within 10 minutes after administration of mivacurium |
| Laryngeal morbidity | After 24 hours patients are asked about hoarseness and sore throat. Patients who experience either or both will be called 3 days postoperatively again. These two variables are assessed using a numeric ranking scale from 0 to 10. | 24 hours after surgery |
| Amount of ephedrine or metaoxedrine administered | If ephedrine or metaoxedrine is administered after induction of anaesthesia and until the patient is ready for properly positioning for surgery, it will be noted in the CRF, as well as the amount administered. Changes in blood pressure or heart rate are treated according to local guidelines. | within 10 minutes after administration of mivacurium |
| Butyrylcholinesterase activity in a venous blood sample | Butyrylcholinesterase activity in a venous blood sample, and further determination of phenotype and genotype if the activity is low. | within 7 days after administration of mivacurium |